Pulmonary Aspergillosis in a COVID 19 Patient: A Case Report and Literature Review

Fatima Babokh1,2, Btissam Ait boucetta1,2, Soumia Nachat1,2, Fatimzahra Rahali1,2, Awatif El Hakkouni1,2

1Parasitology and mycology laboratory, Arrazi hospital, CHU Mohammed VI, Marrakech, Morocco
2Faculty of Medicine and Pharmacy in Marrakech, Cadi Ayyad University, Marrakech, Morocco

DOI: 10.36348/sjbr.2022.v07i04.007 | Received: 19.03.2022 | Accepted: 22.04.2022 | Published: 30.04.2022

*Corresponding author: Fatima Babokh
Parasitology and mycology laboratory, Arrazi hospital, CHU Mohammed VI, Marrakech, Morocco

Abstract

As the COVID 19 pandemic evolves, concerns about fungal co-infections and superinfections are increasing, mainly towards invasive pulmonary aspergillosis (IPA), which increases significantly the risk of mortality in these patients, thus requiring early detection and diagnosis for better treatment efficiency. We’re describing the case of a young, non-immunocompromised patient with SARS COV 2 infection, who developed an IPA due to *Aspergillus flavus*. 

Keywords: Invasive pulmonary aspergillosis’ Bronchoalveolar lavage’ mycological diagnosis’ COVID-19’ *Aspergillus flavus’.

Copyright © 2022 The Author(s): This is an open-access article distributed under the terms of the Creative Commons Attribution 4.0 International License (CC BY-NC 4.0) which permits unrestricted use, distribution, and reproduction in any medium for non-commercial use provided the original author and source are credited.

INTRODUCTION

Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) can cause direct damage to the airway epithelium, allowing invasion by molds such as *Aspergillus* genus. This superinfection contributes to the worsening of the COVID-19 patients’ condition and increases mortality. (Bartoletti et al., 2021).

We report here a new observation of a young, immunocompetent patient with COVID-19 in whom *Aspergillus flavus* has been identified in a pulmonary specimen.

CASE REPORT

A 17-years-old patient with non-significant medical history, hospitalized for suspected respiratory SARS COV 2 infection (dyspnea, coughing and fever), confirmed by an RT-PCR test (reverse transcriptase polymerase chain reaction) on a nasal swab, was transferred later to an intensive care unit for COVID 19 patients, due to worsening respiratory distress and oxygen desaturation.

The patient received an initial treatment of: antibiotics therapy; amoxicillin-clavulanic acid, corticosteroid therapy (dexamethasone at a dose of 6 mg/ kg/day), preventive anticoagulant and oxygenen therapy; according to the Moroccan treatment guidelines for moderate to severe COVID 19 forms.

His initial blood tests showed a high level of C-reactive protein at 96 mg/L, leukocytosis with a cell count of 12380 cells/mm³, thrombocytosis at 601.10³/mm³, a high D-dimer and LDH values, respectively, of 18.26 µg/mL and 403 U/L, and anemia with a hemoglobin level of 10.3 g/dL. In addition, the liver and kidney function tests were normal. Serologies for viral infections (B and C hepatitis viruses and HIV) were negative. And all bacterial and mycological blood cultures remained sterile. Tuberculosis exploration on respiratory samples by GeneXpert® technique was negative. The control PCR for SARS COV 2 came negative after 15 days of treatment. The patient’s respiratory status was stable with a slight decrease in CRP to 86 mg/L, a decrease in leukocyte count to 10.86.10³/mm³, and platelet count to 430.10³/mm³ and LDH to 341 U/L.

The clinical evolution was marked by a worsening of his respiratory condition, and he was hospitalized in the Pneumology Department. A chest CT-scan showed a necrotizing pleuropneumopathy associated to several bilateral excavated nodules.

Citation: Fatima Babokh, Btissam Ait boucetta, Soumia Nachat, Fatimzahra Rahali, Awatif El Hakkouni (2022). Pulmonary Aspergillosis in a COVID 19 Patient: A Case Report and Literature Review. *Saudi J Biomed Res*, 7(4): 163-167.
A multiplex respiratory PCR was performed and was positive to Pseudomonas aeruginosa and Staphylococcus aureus, the patient was then treated by Ceftriaxone and Gentamycin without any clinical improvement. A bronchial aspiration was performed for mycological testing. Direct microscopic examination of the specimen, and MGG staining showed hyaline septated hyphae with acute angle branching (Figure 1).

**Fig-1: Direct microscopical observation of hyaline septated hyphae with acute angle branching in a bronchial aspirate**

The specimen culture on Sabouraud agar incubated at 35°C for 2 days, showed flat colonies with a woolly to granular texture, a green-yellowish color with a yellowish to brown back (Figure 2).

**Fig-2: Culture growth of flat fungal colonies with a woolly to granular texture, and a green-yellowish color**

Microscopic examination of the colonies after Lactophenol blue staining showed septate and hyaline Hyphae, with regular, long conidiophores, columnar and radiate aspergillate head with spherical vesicle and globose conidia in favor of *Aspergillus flavus* (Figure 3).

**Fig-3: Microscopic examination of the colonies after Lactophenol blue staining**

**DISCUSSION**

SARS COV 2 increases the risk of bacterial and fungal co-infections and superinfections such as invasive pulmonary aspergillosis (IPA), which incidence in (Chong & Neu, 2021) systematic review was of 13.5% (ranging from 2.5% to 35.0%).

As in the case of our patient, patients with SARS COV 2 are prone to develop IPA despite the absence of any underlying risk factor. This may be related to tissue damages in the airway epithelium caused by hyperactivation of inflammatory signaling.
pathways, amplification of the inflammatory response, and secretion of proinflammatory cytokines (TNF, IL1, IL6, and IL10), thus establishing a favorable environment for fungal infections (Cunha et al., 2011, 2012; Huang et al., 2020; Sorci et al., 2011). Other factors have also been incriminated in the occurrence of IPA in patients with COVID 19, including concomitant use of corticosteroids, as shown by several studies (Alanio et al., 2020; Koehler et al., 2020; Rutsaert et al., 2020). It has been found that the use of systemic corticosteroids to reduce the inflammatory response in patients with acute respiratory distress syndrome may increase their vulnerability to develop secondary fungal infections (Du et al., 2020; D. Wang et al., 2020). In our patient case, administration of corticosteroids (Dexamethasone 6 mg/day) for two weeks may have increased his susceptibility for an *Aspergillus* infection.

Patients with IPA on SARS COV 2 may not have typical host factors such as neutropenia, hematologic malignancy, or kidney transplantation (Van de Veerdonk et al., 2017). Even the radiological signs vary widely from excavated nodules, as in the case of our patient, multiple pulmonary nodules, ground-glass opacities, or a reverse halo sign. All these radiological signs can also be observed in COVID 19 uncomplicated with IPA (J. Wang et al., 2020).

The diagnosis is most often made on non-specific clinical and radiological evidence combined with positive mycological results. A chest CT scans, followed with a swab of the lower respiratory tract for mycological examination in search of aspergillus. Galactomannan can also be measured on serum or BAL. intubated COVID-19 patients, tracheal suctioning and non-bronchoscopic lavage can be obtained regularly, reducing the risk of infection.

Early diagnosis of IPA in COVID 19 patients relies on the detection of the fungus in a respiratory specimen. Bronchoalveolar lavage (BAL) and lung biopsy are the samples of choice (Alanio et al., 2020). However, obtaining mycological evidence remains difficult; lung biopsy is a dangerous procedure in this category of patients, and bronchoscopy has a high risk of exposure and contamination toward operators during this pandemic (Blaize et al., 2020). As for the causal species, *Aspergillus* flavus is the second most common mycological agent of IPA after *A. fumigates* (H. Wang et al., 2003). High levels of Galactomannan (Galactomannan index > 2.5) have been observed in patients with suspected IPA associated to Covid 19 (Koehler et al., 2020; Wahidi et al., 2020). It is therefore a non-specific polysaccharide antigen released by *Aspergillus* but also by other fungi like Cryptococcus and Fusarium.

The first-line antifungal treatment to be used for IPA in COVID-19 patients is Voriconazole, with a loading dose of 6 mg/kg twice daily, followed by 4 mg/kg twice daily. It should be used cautiously due to potential drug interaction especially for cardiovascular toxicity in patients receiving anti-SARS-CoV-2 therapy (Baniasad et al., 2015). Isavuconazole can also be used at a loading dose of 200 mg three times daily, followed by 200 mg once daily (12-24 h after the last loading dose). It has the same clinical results as Voriconazole with fewer side effects (Maertens et al., 2016; Mellinghoff et al., 2018). In case of suspected resistance to azoles, liposomal amphotericin B is an alternative treatment at a dose of 3 mg/kg/d. However, the concern for its renal toxicity is particularly relevant for patients who are infected with SARS-CoV-2, because of the renal tropism of this virus (Cornely et al., 2007). Biological monitoring of renal and hepatic function is thus required twice a week during treatment. Echinocandins, which should not be used as monotherapy but rather in combination with azoles, as well as Posaconazole, can be used as a last line treatment option. New classes of antifungals being developed, such as Posmanogepix and Ibrexafungerp, may become alternative treatment options for IPA (Kupferschmidt, 2019). Optimal duration of treatment for IPA is still not well established, ranging from 6 to 12 weeks, and even longer in immunocompromised patients. Chest CT-scan follow-ups to assess the resolution of infiltrates are necessary before any decision to discontinue treatment (Bartoletti et al., 2021).

An increase in mortality rates associated to IPA in COVID19 patients has also been described. In a prospective cohort of 108 critically ill patients with SARS COV 2, over a 30-day period, the highest mortality rate was observed in patients with IPA: 44% versus 19% in patients without pulmonary aspergillosis (White et al., 2021). Thus, IPA appears to be a serious secondary infection in patients with COVID-19 with poor prognosis. Hence, an investigation for IPA in Covid-19 patients should be performed in the following cases (Schauwvliegh et al., 2018):

- Refractory fever for more than 3 days.
- Recurrence of fever after a period longer than 48 hours of remission on antibiotic therapy.
- Refractory respiratory failure for more than 5 to 14 days despite adequate treatment.

**CONCLUSION**

IPA in co-infection or superinfection with SARS COV 2 is a severe condition in terms of prognosis and treatment. Aspergillus s.p.p. can become infectious in these patients even without any recognized risk factor and even after remission of COVID 19. This is why health professionals dealing with COVID-19 pandemic must be vigilant to the risk of fungal complications particularly IPA. Diagnosis remains difficult and relies essentially on mycological evidence by isolation and identification of the fungus from pulmonary specimens and on the search for
Galactomannan antigen in the patients’ serum or BAL fluid.

REFERENCES

- Alanio, A., Dellière, S., Fodil, S., Bretagne, S., & Mégarbane, B. (2020). Prevalence of putative invasive pulmonary aspergillosis in critically ill patients with COVID-19. *The Lancet. Respiratory Medicine*, 8(6), e48–e49. https://doi.org/10.1016/S2213-2600(20)30237-X
- Baniasadi, S., Farzanegan, B., & Alchalshem, M. (2015). Important drug classes associated with potential drug-drug interactions in critically ill patients: Highlights for cardiothoracic intensivists. *Annals of Intensive Care*, 5(1), 44. https://doi.org/10.1186/s13613-015-0086-4
- Bartoletti, M., Pascale, R., Cricca, M., Rinaldi, M., Maccaro, A., Bussini, L., Fornero, G., Tonetti, T., Pizzilli, G., Francalanci, E., Giuntoli, L., Rubin, A., Moroni, A., Ambretti, S., Trapani, F., Vatamanu, O., Ranieri, V. M., Castelli, A., Baiocchi, M., PREDICO Study Group. (2021). Epidemiology of Invasive Pulmonary Aspergillosis Among Intubated Patients With COVID-19: A Prospective Study. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 73(11), e3606–e3614. https://doi.org/10.1093/cid/ciaa1065
- Blaize, M., Mayaux, J., Nabet, C., Lampros, A., Marcelin, A.-G., Thellier, M., Piarroux, R., Demoule, A., & Fekkar, A. (2020). Fatal Invasive Aspergillosis and Coronavirus Disease in an Immunocompetent Patient. *Emerging Infectious Diseases*, 26(7), 1636–1637. https://doi.org/10.3201/eid2607.201603
- Chong, W. H., & Neu, K. P. (2021). Incidence, diagnosis and outcomes of COVID-19-associated pulmonary aspergillosis (CAPA): A systematic review. *The Journal of Hospital Infection*, 113, 115–129. https://doi.org/10.1016/j.jhin.2021.04.012
- Cornely, O. A., Maertens, J., Bresnik, M., Ebrahimi, R., Ullmann, A. J., Bouza, E., Heussel, C. P., Lortholary, O., Rieger, C., Boehme, A., Aoun, M., Horst, H.-A., Thiebaut, A., Ruhnke, M., Reichert, D., Vianelli, N., Krause, S. W., Olavarria, E., Herbrecht, R., & AmBiLoad Trial Study Group. (2007). Liposomal amphotericin B as initial therapy for invasive mold infection: A randomized trial comparing a high-loading dose regimen with standard dosing (AmBiLoad trial). *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 44(10), 1289–1297. https://doi.org/10.1086/514341
- Cunha, C., Carvalho, A., Esposito, A., Bistoni, F., & Romani, L. (2012). DAMP signaling in fungal infections and diseases. *Frontiers in Immunology*, 3, 286. https://doi.org/10.3389/fimmu.2012.00286
- Cunha, C., Giovannini, G., Pierini, A., Bell, A. S., Sorci, G., Ruzzi, F., Donato, R., Rodrigues, F., Velardi, A., Aversa, F., Romani, L., & Carvalho, A. (2011). Genetically-Determined Hyperfunction of the S100B/RAGE Axis Is a Risk Factor for Aspergillosis in Stem Cell Transplant Recipients. *PLoS ONE*, 6(11), e27962. https://doi.org/10.1371/journal.pone.0027962
- Du, Y., Tu, L., Zhu, P., Mu, M., Wang, R., Yang, P., Wang, X., Hu, C., Ping, R., Hu, P., Li, T., Cao, F., Chang, C., Hu, Q., Jin, Y., & Xu, G. (2020). Clinical Features of 85 Fatal Cases of COVID-19 from Wuhan. A Retrospective Observational Study. *American Journal of Respiratory and Critical Care Medicine*, 201(11), 1372–1379. https://doi.org/10.1164/rccm.202003-0543OC
- Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., Zhang, L., Fan, G., Xu, J., Gu, X., Cheng, Z., Yu, T., Xia, J., Wei, Y., Wu, W., Xie, X., Yin, W., Li, H., Liu, M., … Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. *The Lancet*, 395(10223), 497–506. https://doi.org/10.1016/S0140-6736(20)30183-5
- Koehler, P., Cornely, O. A., Böttiger, B. W., Dusse, F., Eichenauer, D. A., Fuchs, F., Hallek, M., Jung, N., Klein, F., Persigehl, T., Rybniker, J., Kochanek, M., Böll, B., & Shimabukuro-Vornhagen, A. (2020). COVID-19 associated pulmonary aspergillosis. *Mycoses*, 63(6), 528–534. https://doi.org/10.1111/myc.13096
- Kupferschmidt, K. (2019). New drugs target growing threat of fatal fungi. *Science (New York, N.Y.)*, 366(6464), 407. https://doi.org/10.1126.science.366.6464.407
- Maertens, J. A., Raad, I. I., Marr, K. A., Patterson, T. F., Kontoyiannis, D. P., Cornely, O. A., Bow, E. J., Rahav, G., Neofytos, D., Aoun, M., Baddley, J. W., Giladi, M., Heinz, W. J., Herbrecht, R., Hope, W., Karthaus, M., Lee, D.-G., Lortholary, O., Morrison, V. A., … Ullmann, A. J. (2016). Isavuconazole versus voriconazole for primary treatment of invasive mould disease caused by Aspergillus and other filamentous fungi (SECURE): A phase 3, randomised-controlled, non-inferiority trial. *Lancet (London, England)*, 387(10020), 760–769. https://doi.org/10.1016/S0140-6736(15)01159-9
- Mellinghoff, S. C., Bassetti, M., Dörfel, D., Hagel, S., Lehners, N., Plis, A., Schalk, E., Vena, A., & Cornely, O. A. (2018). Isavuconazole shortens the QTc interval. *Mycoses*, 61(4), 256–260. https://doi.org/10.1111/myc.12731
- Rutsaert, L., Steinfort, N., Van Hunsel, T., Bomans, P., Naens, R., Mertes, H., Dits, H., & Van Regenmortel, N. (2020). COVID-19-associated invasive pulmonary aspergillosis. *Annals of Intensive Care*, 10(1), 71. https://doi.org/10.1186/s13613-020-00886-4
• Schauwvlieghe, A. F. A. D., Rijnders, B. J. A., Philips, N., Verwijs, R., Vanderbeke, L., Van Tienen, C., Lagrou, K., Verweij, P. E., Van de Veerdonk, F. L., Gommer, D., Spronk, P., Bergmans, D. C. J. J., Hoedemaekers, A., Andrinopoulou, E.-R., van den Berg, C. H. S. B., Juffermans, N. P., Hodiamont, C. J., Vonk, A. G., Depuydt, P., ... Dutch-Belgian Mycosis study group. (2018). Invasive aspergillosis in patients admitted to the intensive care unit with severe influenza: A retrospective cohort study. *The Lancet. Respiratory Medicine*, 6(10), 782–792. https://doi.org/10.1016/S2213-2600(18)30274-1

• Sorci, G., Giovannini, G., Riuzzi, F., Bonifazi, P., Zelante, T., Zagarella, S., Bistoni, F., Donato, R., & Romani, L. (2011). The Danger Signal S100B Integrates Pathogen– and Danger–Sensing Pathways to Restrain Inflammation. *PLoS Pathogens*, 7(3), e1001315. https://doi.org/10.1371/journal.ppat.1001315

• van de Veerdonk, F. L., Kolwijck, E., Lestrade, P. P. A., Hodiamont, C. J., Rijnders, B. J. A., van Paassen, J., Haas, P.-J., Oliveira Dos Santos, C., Kampinga, G. A., Bergmans, D. C. J. J., van Dijk, K., de Haan, A. F. J., van Dissel, J., van der Hoeven, H. G., Verweij, P. E., & Dutch Mycoses Study Group. (2017). Influenza-Associated Aspergillosis in Critically Ill Patients. *American Journal of Respiratory and Critical Care Medicine*, 196(4), 524–527. https://doi.org/10.1164/rcrm.201612-2540LE

• Wahidi, M. M., Lamb, C., Murgu, S., Musani, A., Shojaee, S., Sachdeva, A., Maldonado, F., Mahmood, K., Kinsey, M., Sethi, S., Mahajan, A., Majid, A., Keyes, C., Alraiyes, A. H., Sung, A., Hsia, D., & Eapen, G. (2020). American Association for Bronchology and Interventional Pulmonology (AABIP) Statement on the Use of Bronchoscopy and Respiratory Specimen Collection in Patients With Suspected or Confirmed COVID-19 Infection. *Journal of Bronchotherapy & Interventional Pulmonology*, 27(4), e52–e54. https://doi.org/10.1097/LBR.0000000000000681

• Wang, D., Hu, B., Hu, C., Zhu, F., Liu, X., Zhang, J., Wang, B., Xiang, H., Cheng, Z., Xiong, Y., Zhao, Y., Li, Y., Wang, X., & Peng, Z. (2020). Clinical Characteristics of 138 Hospitalized Patients With 2019 Novel Coronavirus-Infected Pneumonia in Wuhan, China. *JAMA*, 323(11), 1061–1069. https://doi.org/10.1001/jama.2020.1585

• Wang, H., Ding, Y., Li, X., Yang, L., Zhang, W., & Kang, W. (2003). Fatal aspergillosis in a patient with SARS who was treated with corticosteroids. *The New England Journal of Medicine*, 349(5), 507–508. https://doi.org/10.1056/NEJM200307313490519

• Wang, J., Yang, Q., Zhang, P., Sheng, J., Zhou, J., & Qu, T. (2020). Clinical characteristics of invasive pulmonary aspergillosis in patients with COVID-19 in Zhejiang, China: A retrospective case series. *Critical Care (London, England)*, 24(1), 299. https://doi.org/10.1186/s13054-020-03046-7

• White, P. L., Dhillon, R., Cordey, A., Hughes, H., Faggian, F., Soni, S., Pandey, M., Whitaker, H., May, A., Morgan, M., Wise, M. P., Healy, B., Blyth, I., Price, J. S., Vale, L., Posso, R., Kronda, J., Blackwood, A., Rafferty, H., ... Backx, M. (2021). A National Strategy to Diagnose Coronavirus Disease 2019-Associated Invasive Fungal Disease in the Intensive Care Unit. *Clinical Infectious Diseases: An Official Publication of the Infectious Diseases Society of America*, 73(7), e1634–e1644. https://doi.org/10.1093/cid/ciaa1298